(CYTK) Cytokinetics - Overview
Stock: Cardiac Activator, Cardiac Inhibitor, Skeletal Activator
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 54.4% |
| Relative Tail Risk | -14.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.84 |
| Alpha | 25.96 |
| Character TTM | |
|---|---|
| Beta | 0.613 |
| Beta Downside | 0.426 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.39% |
| CAGR/Max DD | 0.18 |
Description: CYTK Cytokinetics January 08, 2026
Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biopharma focused on small-molecule modulators of muscle contractility. Its pipeline includes the cardiac myosin activator omecamtiv mecarbil (Phase III heart-failure trial), the fast skeletal muscle troponin activator CK-089 (Phase I), the cardiac myosin inhibitor CK-586 (Phase II), and aficamten, an oral cardiac myosin inhibitor now in Phase III for hypertrophic cardiomyopathy (HCM). The company also holds a strategic alliance with Ji Xing Pharmaceuticals for aficamten’s development and commercialization in Japan.
Key quantitative context (as of FY 2023): cash and short-term investments of roughly $380 million, giving a runway of ~2 years at current burn rates; market capitalization around $1.1 billion, reflecting a price-to-sales multiple of ~30× the modest 2022 revenue of $35 million. The U.S. heart-failure therapeutic market is projected to exceed $5 billion by 2028, while HCM prevalence (≈0.2 % of adults) supports a niche market valued at $1–2 billion, both of which are driving investor interest in muscle-targeted therapeutics. Biotech sector R&D intensity remains high, with average R&D spend ≈25 % of revenue, underscoring the importance of cash efficiency for CYTK’s upcoming trial readouts.
For a deeper, data-driven look at CYTK’s valuation dynamics, you might find ValueRay’s analytical platform worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -751.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -3.22 > 1.0 |
| NWC/Revenue: 957.7% < 20% (prev 28.2k%; Δ -27.3k% < -1%) |
| CFO/TA -0.30 > 3% & CFO -432.9m > Net Income -751.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (120.0m) vs 12m ago 1.95% < -2% |
| Gross Margin: -127.5% > 18% (prev -101.8%; Δ -2578 % > 0.5%) |
| Asset Turnover: 6.07% > 50% (prev 0.22%; Δ 5.85% > 0%) |
| Interest Coverage Ratio: -6.82 > 6 (EBITDA TTM -646.2m / Interest Expense TTM 96.1m) |
Altman Z'' -8.52
| A: 0.58 (Total Current Assets 977.3m - Total Current Liabilities 142.1m) / Total Assets 1.44b |
| B: -2.30 (Retained Earnings -3.30b / Total Assets 1.44b) |
| C: -0.46 (EBIT TTM -655.8m / Avg Total Assets 1.44b) |
| D: -1.69 (Book Value of Equity -3.30b / Total Liabilities 1.96b) |
| Altman-Z'' Score: -8.52 = D |
Beneish M 1.00
| DSRI: 0.27 (Receivables 1.81m/244.0k, Revenue 87.2m/3.22m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.10 (AQ_t 0.21 / AQ_t-1 0.19) |
| SGI: 27.09 (Revenue 87.2m / 3.22m) |
| TATA: -0.22 (NI -751.9m - CFO -432.9m) / TA 1.44b) |
| Beneish M-Score: 14.92 (Cap -4..+1) = D |
What is the price of CYTK shares?
Over the past week, the price has changed by -2.76%, over one month by +1.36%, over three months by +1.86% and over the past year by +50.11%.
Is CYTK a buy, sell or hold?
- StrongBuy: 9
- Buy: 9
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CYTK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 89.4 | 41.2% |
| Analysts Target Price | 89.4 | 41.2% |
| ValueRay Target Price | 71.6 | 13% |
CYTK Fundamental Data Overview February 03, 2026
P/B = 60.3093
P/EG = -0.42
Revenue TTM = 87.2m USD
EBIT TTM = -655.8m USD
EBITDA TTM = -646.2m USD
Long Term Debt = 1.05b USD (from longTermDebt, last quarter)
Short Term Debt = 37.9m USD (from shortTermDebt, last quarter)
Debt = 1.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.3m USD (from netDebt column, last quarter)
Enterprise Value = 7.96b USD (7.73b + Debt 1.20b - CCE 962.5m)
Interest Coverage Ratio = -6.82 (Ebit TTM -655.8m / Interest Expense TTM 96.1m)
EV/FCF = -17.56x (Enterprise Value 7.96b / FCF TTM -453.4m)
FCF Yield = -5.70% (FCF TTM -453.4m / Enterprise Value 7.96b)
FCF Margin = -519.9% (FCF TTM -453.4m / Revenue TTM 87.2m)
Net Margin = -862.2% (Net Income TTM -751.9m / Revenue TTM 87.2m)
Gross Margin = -127.5% ((Revenue TTM 87.2m - Cost of Revenue TTM 198.4m) / Revenue TTM)
Gross Margin QoQ = -38.38% (prev none%)
Tobins Q-Ratio = 5.54 (Enterprise Value 7.96b / Total Assets 1.44b)
Interest Expense / Debt = 2.20% (Interest Expense 26.3m / Debt 1.20b)
Taxrate = 21.0% (US default 21%)
NOPAT = -518.1m (EBIT -655.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.88 (Total Current Assets 977.3m / Total Current Liabilities 142.1m)
Debt / Equity = -2.30 (negative equity) (Debt 1.20b / totalStockholderEquity, last quarter -521.1m)
Debt / EBITDA = -1.50 (negative EBITDA) (Net Debt 968.3m / EBITDA -646.2m)
Debt / FCF = -2.14 (negative FCF - burning cash) (Net Debt 968.3m / FCF TTM -453.4m)
Total Stockholder Equity = -322.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.35% (Net Income -751.9m / Total Assets 1.44b)
RoE = 232.9% (negative equity) (Net Income TTM -751.9m / Total Stockholder Equity -322.9m)
RoCE = -90.41% (EBIT -655.8m / Capital Employed (Equity -322.9m + L.T.Debt 1.05b))
RoIC = -114.1% (out of range, set to none) (NOPAT -518.1m / Invested Capital 454.2m)
WACC = 7.31% (E(7.73b)/V(8.92b) * Re(8.17%) + D(1.20b)/V(8.92b) * Rd(2.20%) * (1-Tc(0.21)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.05%
Fair Price DCF = unknown (Cash Flow -453.4m)
EPS Correlation: -2.87 | EPS CAGR: 13.59% | SUE: 4.0 | # QB: 1
Revenue Correlation: -18.06 | Revenue CAGR: -59.15% | SUE: -0.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.57 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-5.95 | Chg30d=-0.126 | Revisions Net=+0 | Growth EPS=+2.8% | Growth Revenue=+52.6%